Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Apr 21, 2015; 21(15): 4696-4706
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4696
Figure 3
Figure 3 ∆ alpha-fetoprotein decline and %∆ alpha-fetoprotein decline by baseline alpha-fetoprotein level (≥ 10 ng/mL and < 10 ng/mL). ∆AFP decline is defined as the AFP level at 24 wk after end of treatment subtracted from baseline. %∆AFP decline is defined as the percentage of AFP at 24 wk after end of treatment subtracted from baseline. The vertical bars represent the standard errors of the mean. Dual therapy: Pegylated-interferon-α and ribavirin; Triple therapy: Telaprevir-based therapy combined with pegylated-interferon-α and ribavirin; AFP: Alpha-fetoprotein.